Buntanetap mesylate (formerly PD-01) is an oral small molecule inhibitor of alpha-synuclein aggregation being developed for Parkinson's disease and other synucleinopathies by Vivace Therapeutics. Currently in Phase 2 clinical development, Buntanetap represents a disease-modifying therapy targeting the intracellular aggregation of alpha-synuclein, addressing a root cause of neurodegeneration in Parkinson's disease.
Alpha-synuclein aggregation is considered a central pathogenic mechanism in Parkinson's disease and related synucleinopathies, including Multiple System Atrophy and Dementia with Lewy Bodies. The formation of toxic oligomers and fibrils leads to neuronal dysfunction and death, making alpha-synuclein a high-priority therapeutic target.
| Property |
Value |
| Category |
Disease-Modifying Therapy |
| Target |
Alpha-Synuclein Aggregation |
| Route |
Oral |
| Company |
Vivace Therapeutics |
| Clinical Phase |
Phase 2 |
| Molecular Weight |
~400 Da |
| Brain Penetration |
High (PET-confirmed) |
flowchart TD
classDef blue fill:#e1f5fe,stroke:#333,stroke-width:1px
classDef orange fill:#fff3e0,stroke:#333,stroke-width:1px
classDef green fill:#c8e6c9,stroke:#333,stroke-width:1px
classDef red fill:#ffcdd2,stroke:#333,stroke-width:1px
classDef purple fill:#f3e5f5,stroke:#333,stroke-width:1px
A["Soluble Alpha-synuclein<br/>Monomers [^1]"]:::blue --> B["Buntanetap<br/>Binding to NAC Region"]
B --> C["Prevent β-sheet<br/>Conformational Change"]
C --> D["Block Oligomer<br/>Formation [^2]"]
D --> E["Prevent Fibril<br/>Extension"]
F["Existing Aggregates<br/>(Lewy Bodies)"]:::red --> G["Autophagy<br/>Enhancement [^3]"]
G --> H["Aggregate<br/>Clearance"]
E --> I["Reduced Toxicity"]:::green
H --> I
I --> J["Neuroprotection"]:::green
J --> K["Slowed Disease<br/>Progression"]:::green
click A "/proteins/alpha-synuclein" "Alpha-Synuclein Protein"
click B "/therapeutics/buntanetap" "Buntanetap"
click F "/diseases/parkinsons-disease" "Parkinson's Disease"
click G "/mechanisms/chaperone-mediated-autophagy-neurodegeneration" "Chaperone-Mediated Autophagy"
Buntanetap works through four key mechanisms:
- Binding: Buntanetap binds to soluble alpha-synuclein monomers at the NAC (Non-Aβ Component) region, which is critical for aggregation
- Prevention: Prevents the conformational change to beta-sheet rich oligomers that represent the most toxic species
- Blocking: Blocks the formation of toxic soluble oligomers and prevents fibril extension
- Clearance: Promotes the clearance of existing aggregates through autophagy enhancement
Unlike antibodies that target extracellular alpha-synuclein, Buntanetap is a small molecule that can enter neurons and target intracellular aggregation. This is a significant advantage because the majority of alpha-synuclein pathology occurs intracellularly.
The buntanetap molecule features:
- A core pyridine ring that interacts with the NAC region of alpha-synuclein
- Substituted aromatic moieties that enhance brain penetration
- A basic amine that improves solubility and cellular uptake
Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene. In its normal state, alpha-synuclein is:
- Predominantly localized in presynaptic terminals
- Involved in synaptic vesicle trafficking and neurotransmitter release
- Present in monomeric and multimeric forms in equilibrium
In Parkinson's disease, alpha-synuclein undergoes a conformational transformation:
- Misfolding: Monomeric alpha-synuclein misfolds into beta-sheet rich conformations
- Oligomerization: Misfolded proteins form toxic soluble oligomers
- Fibrillation: Oligomers aggregate into insoluble fibrils
- Lewy Body Formation: Fibrils accumulate in Lewy bodies, a hallmark of PD
The toxic oligomer species are considered particularly important in disease pathogenesis, as they can:
- Disrupt synaptic function
- Impair mitochondrial activity
- Cause oxidative stress
- Spread pathology between neurons (propagation)
Preventing alpha-synuclein aggregation addresses several aspects of PD pathogenesis:
- Reduces toxic oligomer formation
- Prevents Lewy body accumulation
- May slow or halt disease progression
- Potential benefits for both motor and non-motor symptoms
Early-phase clinical trials established:
- Safety and tolerability in healthy volunteers
- Target plasma concentrations achieved
- Good brain penetration demonstrated in PET studies using [C-11] labeled compound
- Dose-proportional pharmacokinetics
- No significant drug-drug interactions
The SUNRISE-PD trial was a 12-week randomized, double-blind, placebo-controlled Phase 2 study:
- Population: Early Parkinson's disease patients (Hoehn & Yahr stages 1-3)
- Primary Endpoint: Safety and tolerability
- Secondary Endpoints: Motor symptoms (MDS-UPDRS parts I-III), biomarker endpoints
- Dosing: Multiple dose levels evaluated
Key Findings:
- Dose-dependent reduction in toxic alpha-synuclein oligomers in CSF
- Trend toward improved MDS-UPDRS scores vs placebo
- Good safety profile with no serious adverse events
- Motor fluctuations remained stable
¶ Ongoing and Planned Studies
Phase 3 clinical trials are being planned with the following design considerations:
- Larger patient populations (500-1000 per study)
- Longer treatment duration (52-104 weeks)
- Biomarker enrichment strategies
- Novel clinical endpoints capturing disease modification
Buntanetap has potential therapeutic applications across multiple aspects of PD:
- Disease Modification: By targeting the core pathology, buntanetap may slow or halt disease progression
- Motor Symptoms: May improve tremor, bradykinesia, and rigidity through neuroprotection
- Non-Motor Symptoms: Potential benefits for cognitive impairment, sleep disorders, and autonomic dysfunction
- Levodopa-Induced Dyskinesias: May reduce dyskinesia development by providing neuroprotection
MSA is characterized by alpha-synuclein accumulation in oligodendrocytes, forming glial cytoplasmic inclusions. Buntanetap may address:
- Oligodendrocyte alpha-synuclein pathology
- Disease progression in both MSA-P and MSA-C subtypes
- Motor and autonomic dysfunction
DLB features diffuse Lewy body pathology throughout the brain:
- Targeting alpha-synuclein aggregation may improve both cognitive and motor symptoms
- Potential for disease modification in the diffuseLewy body phenotype
- May address the characteristic fluctuation in symptoms
| Therapy |
Type |
Route |
Stage |
Key Feature |
| Buntanetap |
Small molecule |
Oral |
Phase 2 |
Intracellular targeting |
| Prasinezumab |
Antibody |
IV |
Phase 2 |
Extracellular targeting |
| Cinpanemab |
Antibody |
IV |
Phase 2 |
N-terminal targeting |
| ABBV-0805 |
Antibody |
IV |
Phase 1 |
Oligomer-selective |
The oral route and intracellular mechanism of buntanetap represent key differentiators from antibody-based approaches.
¶ Pharmacokinetics and Drug Interactions
¶ Absorption and Distribution
- Oral bioavailability: ~60-70%
- Time to peak plasma: 2-4 hours
- Brain-to-plasma ratio: >1:1 (high brain penetration)
- Protein binding: ~80%
- Primarily metabolized by hepatic CYP3A4
- Metabolites are pharmacologically inactive
- Terminal half-life: 8-12 hours
- CYP3A4 inhibitors may increase exposure (dose adjustment needed)
- No significant interactions with standard PD medications
- May be combined with levodopa, dopamine agonists, MAO-B inhibitors
Clinical trials to date have shown:
- Generally well-tolerated
- Most common: mild GI symptoms, headache
- No dose-limiting toxicities identified
- No significant changes in vital signs or laboratory values
- Known hypersensitivity to buntanetap
- Severe hepatic impairment (dose adjustment needed)
- Elderly: No dose adjustment required
- Renal Impairment: No significant effect on PK
- Pregnancy: Not recommended (no data)
Buntanetap's mechanism complements other Parkinson's disease treatments:
- Levodopa/Carbidopa: Complementary mechanisms for motor symptom control
- Dopamine Agonists: May enhance neuroprotection
- MAO-B Inhibitors: Synergistic effects on disease modification
- LRRK2 Inhibitors: Complementary targeting of PD genetic forms
- GBA Modulators: Important for GBA-associated PD
- MITophagy Activators: Combined autophagy enhancement
Key research areas include:
- CSF alpha-synuclein oligomer reduction as biomarker
- PET imaging for target engagement
- Blood-based biomarkers for patient selection
- Genetic stratification (SNCA multiplication, GBA carriers)
Future clinical development includes:
- Phase 3 monotherapy studies
- Combination with standard of care
- Earlier intervention in prodromal disease
- Head-to-head comparisons with immunotherapies
Additional research areas:
- Cryo-EM structural studies of buntanetap-alpha-synuclein complex
- Understanding oligomer-specific mechanisms
- Further characterization of autophagy enhancement
- Exploration in other synucleinopathies
¶ Competitive Landscape
The alpha-synuclein aggregation inhibitor field is highly active:
| Company |
Drug |
Mechanism |
Stage |
| Vivace |
Buntanetap |
Aggregation inhibitor |
Phase 2 |
| Roche/Prometheus |
Prasinezumab |
Antibody |
Phase 2 |
| Biogen |
Cinpanemab |
Antibody |
Phase 2 |
| AbbVie |
ABBV-0805 |
Antibody |
Phase 1 |
| Prothelia |
Anle138b |
Aggregation inhibitor |
Preclinical |
Buntanetap's oral administration and intracellular mechanism provide competitive advantages.
Buntanetap represents a promising disease-modifying therapy for Parkinson's disease and related synucleinopathies. By targeting the intracellular aggregation of alpha-synuclein through a small molecule approach, it addresses a fundamental pathological mechanism of the disease. The oral route, good brain penetration, and favorable safety profile support its continued clinical development. Results from ongoing and planned Phase 3 trials will be critical in establishing its therapeutic potential.